Celesteion™ PUREViSION Edition PET/CT
44-year-old female post treatment for right frontal anaplastic oligodendroglioma.
10.8 mCi F-18 FDG was injected intravenously. PET scan and localizing CT images without iodinated contrast were acquired on a Canon Medical Systems Celesteion™ PUREViSION Edition PET/CT 60 minutes post injection.
PET/CT scan demonstrates postoperative hypometabolic changes to the right frontal lobe. No residual tumor is seen.
The preferred treatment for brain tumors is surgical excision. PET scans are useful for evaluating the efficacy of surgical procedures.
PET | |
Region Covered | Brain |
Injected Dose | 10.8 mCi of 18F-FDG |
Acquisition Time | 15 min/bed |
Number of Beds | 1 |
Uptake Time | 60 min |
Glucose Level | 99 mg/dl |
Reconstruction | TOF |
CT | |
Scan Mode | Helical |
Collimation | 0.5 mm x 16 |
kVp | 120 |
mAs | 210 |
Rotation Time | 0.75 s |
Scan Range | 200 mm |
Dose Reduction | AIDR3D |
CTDIvol | 59.5 mGy |
DLP | 1190.0 mGy•cm |
63-year-old male with history of remote MVA, recent memory loss and dizziness.
14.6mCi F-18 FDG was injected intravenously. Low dose CT and PET images were acquired on a Canon Medical Systems Celesteion™ PUREViSION Edition PET/CT.
Quantifiable areas of significantly diminished metabolism in the right frontal lobe, both parietal lobes, right temporal lobe, and both occipital lobes. Finding is compatible with a primary neurodegenerative process.
PET | |
Region Covered | Brain |
Injected Dose | 14.6 mCi of 18F-FDG |
Acquisition Time | 15 min/bed |
Number of Beds | 1 |
Uptake Time | 60 min |
Glucose Level | 98 mg/dl |
Reconstruction | TOF |
CT | |
Scan Mode | Static |
Collimation | 0.5 mm x 16 |
kVp | 120 |
mAs | 210 |
Rotation Time | 0.75 s |
Scan Range | 200 mm |
Rotation Time | 0.75 s |
Scan Range | 200 mm |
CTDIvol | 59.5 mGy |
DLP | 1190.0 mGy•cm |
© Canon Medical Systems Asia Pte. Ltd.
© Canon Medical Systems Asia Pte. Ltd.